Personalized Medicine Not Paying The Bills Yet; More Science Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is on board with companion diagnostics, but physicians don’t know what to do with the tests.
You may also be interested in...
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.
Industry Involvement In Guidance Development Encouraged By FDA Working Group
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.